The present study evaluated the prognostic significance of serum GDF-15 and IL-6 levels in patients undergoing immunotherapy for advanced malignancies, including NSCLC, RCC, and malignant melanoma. This evidence concerns the gene GDF15 and renal cell carcinoma.